Drug Search Results
More Filters [+]

EP-547

Alternative Names: ep-547, ep 547, ep547
Latest Update: 2024-06-12
Latest Update Note: News Article

Product Description

Escient Pharmaceuticals is developing EP-547, an MRGPRX4-targeted oral therapy, as a treatment for cholestatic and uremic pruritus. (Sourced from: https://www.escientpharma.com/escient-pharmaceuticals-announces-positive-results-from-phase-1-study-of-ep547-an-mrgprx4-targeted-oral-therapy-for-cholestatic-and-uremic-pruritus/)

Mechanisms of Action: MRGPRX4 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Escient Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EP-547

Countries in Clinic: Australia, Belgium, Canada, France, Israel, Netherlands, New Zealand, Spain, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Biliary Cirrhosis|Cholangitis, Sclerosing|Liver Cirrhosis|Pruritus

Phase 1: Cholestasis|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PACIFIC

P2

Active, not recruiting

Cholangitis, Sclerosing|Liver Cirrhosis|Biliary Cirrhosis|Pruritus

2024-07-01

24%

PACIFIC

P2

Active, not recruiting

Cholangitis, Sclerosing|Biliary Cirrhosis|Pruritus

2024-05-03

EP-547-101

P1

Completed

Cholestasis|Kidney Diseases|Pruritus

2021-07-08

Recent News Events